Asmanex Hfa is a drug owned by Organon Llc. It is protected by 7 US drug patents filed in 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 12, 2023. Details of Asmanex Hfa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6068832 | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
Aug, 2017
(7 years ago) |
Expired
|
|
US6057307 (Pediatric) | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
|
US6365581 (Pediatric) | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
|
US5889015 (Pediatric) | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(10 years ago) |
Expired
|
| US6365581 | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
| US5889015 | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
| US6057307 | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) |
Expired
|
FDA has granted several exclusivities to Asmanex Hfa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Asmanex Hfa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Asmanex Hfa.
Exclusivity Information
Asmanex Hfa holds 2 exclusivities. All of its exclusivities have expired in 2023. Details of Asmanex Hfa's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 12, 2022 |
| Pediatric Exclusivity(PED) | Feb 12, 2023 |
US patents provide insights into the exclusivity only within the United States, but Asmanex Hfa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Asmanex Hfa's family patents as well as insights into ongoing legal events on those patents.
Asmanex Hfa's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Asmanex Hfa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 12, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Asmanex Hfa Generic API suppliers:
Mometasone Furoate is the generic name for the brand Asmanex Hfa. 14 different companies have already filed for the generic of Asmanex Hfa, with Cosette having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Asmanex Hfa's generic
Alternative Brands for Asmanex Hfa
Asmanex Hfa which is used for the treatment of asthma., has several other brand drugs in the same treatment category and using the same active ingredient (Mometasone Furoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Organon Llc |
| |||||
| Teva Pharm |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Mometasone Furoate. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Mometasone Furoate, Asmanex Hfa's active ingredient. Check the complete list of approved generic manufacturers for Asmanex Hfa
About Asmanex Hfa
Asmanex Hfa is a drug owned by Organon Llc. It is used for the treatment of asthma. Asmanex Hfa uses Mometasone Furoate as an active ingredient. Asmanex Hfa was launched by Organon Llc in 2019.
Approval Date:
Asmanex Hfa was approved by FDA for market use on 12 August, 2019.
Active Ingredient:
Asmanex Hfa uses Mometasone Furoate as the active ingredient. Check out other Drugs and Companies using Mometasone Furoate ingredient
Treatment:
Asmanex Hfa is used for the treatment of asthma.
Dosage:
Asmanex Hfa is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.10MG/INH | AEROSOL, METERED | Prescription | INHALATION |
| 0.20MG/INH | AEROSOL, METERED | Prescription | INHALATION |